Immune gene therapy of cancer

Area of Science:

• Oncology
• Immunology
• Gene Therapy

Background:

• Cancer gene therapy initially showed promise but faced setbacks, diminishing its popularity.
• Immunotherapy, despite early promise in the 1980s, also experienced a decline before its resurgence.
• The advent of immune checkpoint inhibitors approximately a decade ago revitalized immunotherapy as a major cancer treatment option.

Purpose of the Study:

• To highlight the evolution and resurgence of cancer gene therapy and immunotherapy.
• To emphasize the integration of immune gene therapy into mainstream cancer treatment modalities.

Main Methods:

• Review of historical trends in cancer treatment modalities.
• Identification of key advancements such as oncolytic viruses and Chimeric antigen receptor (CAR) T-cells.
• Analysis of the synergistic impact of gene therapy on immunotherapy.

Main Results:

• Cancer gene therapy and immunotherapy have overcome initial challenges to become vital treatment options.
• Immune gene therapy, particularly with oncolytic viruses and CAR T-cells, has significantly advanced cancer treatment.
• These advanced therapies are now considered essential alongside surgery, radiotherapy, chemotherapy, and targeted therapies.

Conclusions:

• The combination of gene therapy and immunotherapy represents a significant leap forward in oncology.
• Immune gene therapy is now a cornerstone of modern cancer care, offering new hope for patients.